A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-22. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Tokusou Sentai Dekaranger (特捜戦隊デカレンジャー, Tokusō Sentai Dekarenjā) is a Japanese tokusatsu series that serves as the 28th installment in the Super Sentai franchise and the 16th entry in the Heisei era. In an iteration of the planet Earth where extraterrestrial contact is possible, the S.P.D. (Special Police Dekaranger) battles alien criminals collectively called "Alienizers".
And that's the S&D Group." One of the assistants whose flats were searched (Giuseppe Meroni) works for the EPP member Lara Comi, and the EPP member Maria Spyraki was later also put under investigation by the European Public Prosecutor's Office (EPPO). The S&D Group commissioned an inquiry conducted from March to June 2023 by three independent experts: former MEP Richard Corbett, auditor and governance expert Jean-Pierre Garitte, and expert in economic criminal law Silvina Bacigalupo. They presented their initial report to the Group in July. It warned of a heightened risk of geostrategic interference and geostrategic corruption and warned that the EU institutions need to strengthen their resilience by updating their rules and procedures. It pointed out that the existing regulatory framework laying down ethical requirements for MEPs and staff is distributed over at least 27 different documents at various levels of the legal hierarchy, from treaty-level provisions to EU legislation, inter-institutional agreements, parliamentary rules of procedure, the MEP code of conduct and a range of decisions by the Parliament, its Bureau, the Conference of Presidents and the Secretary General. The report identified some 50 shortcomings in them, from gaps to contradictions, weak wording, unclear obligations and inadequate enforcement. This part of the report fed into the subsequent revision of the European Parliament's Rules of Procedure and the Code of Conduct for Members (see below) adopted in September 2023.
=== Special screening === A special 35mm screening of the film was organized by Austin's Alamo Drafthouse theater on May 4, 2014, in presence of Bosworth who took part in a Q&A session with the audience.
== Books and articles == Dobbs, G. Michael (2015). Escape – How Animation Broke into the Mainstream in the 1990s. Orlando: BearManor Media. ISBN 978-1593931100. Finley, Laura L. (2018). Violence in Popular Culture American and Global Perspectives. Santa Monica: ABC-CLIO. ISBN 9781440854330. Komorowski, Thad (2017). Sick Little Monkeys: The Unauthorized Ren & Stimpy Story. Albany, Georgia: BearManor Media. ISBN 978-1629331836.
The plot of Black Mesa is almost identical to Half-Life's storyline. Like in the original game, the player controls Gordon Freeman, a theoretical physicist working at the Black Mesa Research Facility. He is tasked to place a sample of anomalous material into an Anti-Mass Spectrometer for analysis, using the Mark IV Hazardous Environment Suit (HEV Suit) to do so safely. However, the sample causes a "resonance cascade", devastating the facility and creating an interdimensional rift to an alien dimension called Xen, bringing its alien creatures to Earth. Freeman survives the incident, finds other survivors, and is tasked to make his way to the surface to call for help. Upon reaching the surface, however, he finds that the facility is being cleansed of any and all biological organisms – human or alien – by the military. Freeman learns from the surviving scientists the only way to stop the alien invasion is to cross over to Xen, a border world connecting different universes, and destroy the entity called the Nihilanth keeping the rift open. Freeman is teleported to Xen, destroys the Nihilanth, and ends the alien invasion. He is then detained by the G-Man, a mysterious interdimensional agent who claims his "employers" wish to hire Freeman. If he accepts, Freeman is placed into stasis; if not, he is teleported to his death.
Sources: en.wikipedia.org
== Medical uses == Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. Stimulants produce a noticeable crash or comedown at the end of their effects. In the US, the most frequently prescribed stimulants as of 2013 were lisdexamfetamine (Vyvanse), methylphenidate (Ritalin), and amphetamine (Adderall). It was estimated in 2015 that the percentage of the world population that had used cocaine during a year was 0.4%. For the category "amphetamines and prescription stimulants" (with "amphetamines" including amphetamine and methamphetamine) the value was 0.7%, and for MDMA 0.4%. Stimulants have been used in medicine for many conditions including obesity, sleep disorders, mood disorders, impulse-control disorders, asthma, nasal congestion and, in case of cocaine, as local anesthetics. Drugs used to treat obesity are called anorectics and generally include drugs that follow the general definition of a stimulant, but other drugs such as cannabinoid receptor antagonists also belong to this group. Eugeroics are used in management of sleep disorders characterized by excessive daytime sleepiness, such as narcolepsy, and include stimulants such as modafinil and pitolisant. Stimulants are used in impulse control disorders such as ADHD and off-label in mood disorders such as major depressive disorder to increase energy, focus, and elevate mood.
== Amino acid metabolism == When more sulfur containing amino acids, methionine and cystine, are consumed than the body can use for growth and repair, they are broken down yielding sulfate, or sulfuric acid among other products. Animal foods such as meat, dairy, and eggs are high in protein and "dietary animal protein intake is highly correlated with renal net acid excretion". Research dating back to the early 1900s has shown correlations between high protein diets and increased acid excretion. One measure of the acidic or basic effects foods have in the body is Potential Renal Acid Load (PRAL). Cheeses with protein content of 15 g protein/100g or higher have a high PRAL value of 23.6 mEq/100 g edible portion. Meats, fish, other cheeses and flour or noodles all have a PRAL around 8.0 mEq/100 g edible portion, where fruits and vegetables actually have a negative PRAL. In healthy adults, bone undergoes constant repair and renewal. New bone is deposited by osteoblast cells and resorbed or destroyed by osteoclast cells. This addition and subtraction of bone usually yields no net change in the overall mass of the skeleton, but the turnover process can be significantly affected by pH.
In engineering, the elasticity of a material is quantified by the elastic modulus such as the Young's modulus, bulk modulus or shear modulus which measure the amount of stress needed to achieve a unit of strain; a higher modulus indicates that the material is harder to deform. The SI unit of this modulus is the pascal (Pa). The material's elastic limit or yield strength is the maximum stress that can arise before the onset of plastic deformation. Its SI unit is also the pascal (Pa).
In August 2026, Kyle Hyndman and Alberto Bisin published a replication in Psychological Science of Study 2 from Ariely and Klaus Wertenbroch's 2002 article "Procrastination, Deadlines, and Performance: Self-Control by Precommitment". Their newly collected data did not reproduce the original results: changes in deadline conditions had negligible effects on the three performance measures and several survey measures, and evenly spaced externally imposed deadlines were not especially effective at reducing procrastination. On August 31, 2026, Data Colada researchers Uri Simonsohn, Joe Simmons, and Leif Nelson published an analysis of spreadsheet files that Hyndman said he had received from Ariely's MIT email account in 2006; they reported duplicated observations and several other statistical patterns that they considered inconsistent with genuine data and concluded that the data for Study 2 had been tampered with or fabricated. Ariely had stated earlier that month that he had been informed that the data underlying the paper contained "serious anomalies", that the surviving documentary record and his memory were insufficient to resolve the questions raised, and that he and Wertenbroch were cooperating with the journal's review and retraction processes. Data Colada reported that Wertenbroch had asked the editor to retract the 2002 article, and it was retracted on September 2, 2026.
During embryogenesis and early development, cells switch back and forth between different cellular phenotypes via MET and its reverse process, epithelial–mesenchymal transition (EMT). Developmental METs have been studied most extensively in embryogenesis during somitogenesis and nephrogenesis and carcinogenesis during metastasis, but it also occurs in cardiogenesis or foregut development. MET is an essential process in embryogenesis to gather mesenchymal-like cells into cohesive structures. Although the mechanism of MET during various organs morphogenesis is quite similar, each process has a unique signaling pathway to induce changes in gene expression profiles.
Sources: en.wikipedia.org
Organogenesis, the development of the organs, takes place from the third to the eighth week during embryonic development. The origins of the liver lie in both the ventral portion of the foregut endoderm (endoderm being one of the three embryonic germ layers) and the constituents of the adjacent septum transversum mesenchyme. In the human embryo, the hepatic diverticulum is the tube of endoderm that extends out from the foregut into the surrounding mesenchyme. The mesenchyme of septum transversum induces this endoderm to proliferate, to branch, and to form the glandular epithelium of the liver. A portion of the hepatic diverticulum (that region closest to the digestive tube) continues to function as the drainage duct of the liver, and a branch from this duct produces the gallbladder. Besides signals from the septum transversum mesenchyme, fibroblast growth factor from the developing heart also contributes to hepatic competence, along with retinoic acid emanating from the lateral plate mesoderm. The hepatic endodermal cells undergo a morphological transition from columnar to pseudostratified resulting in thickening into the early liver bud. Their expansion forms a population of the bipotential hepatoblasts. Hepatic stellate cells are derived from mesenchyme. After migration of hepatoblasts into the septum transversum mesenchyme, the hepatic architecture begins to be established, with liver sinusoids and bile canaliculi appearing. The liver bud separates into the lobes. The left umbilical vein becomes the ductus venosus and the right vitelline vein becomes the portal vein.
oxoacid Also oxyacid or oxacid. 1. Any acid having oxygen in the acidic group. 2. Any compound which contains oxygen, at least one other element, and at least one hydrogen atom bound to oxygen, and which produces a conjugate base by the loss of positively charged hydrogen protons.
The United States has been a leader in technological innovation since the late 19th century and scientific research since the mid-20th century. Methods for producing interchangeable parts and the establishment of a machine tool industry enabled the large-scale manufacturing of U.S. consumer products in the late 19th century. By the early 20th century, factory electrification, the introduction of the assembly line, and other labor-saving techniques created the system of mass production. In the 21st century, the United States continues to be one of the world's foremost scientific powers, though China has emerged as a major competitor in many fields. The U.S. has the highest research and development expenditures of any country and ranks ninth as a percentage of GDP. In 2022, the United States was (after China) the country with the second-highest number of published scientific papers. In 2021, the U.S. ranked second (also after China) by the number of patent applications, and third by trademark and industrial design applications (after China and Germany), according to World Intellectual Property Indicators. In 2025 the United States ranked third (after Switzerland and Sweden) in the Global Innovation Index. The United States is considered to be a world leader in the development of artificial intelligence technology. In 2023, the United States was ranked the second most technologically advanced country in the world (after South Korea) by Global Finance magazine.
=== Classification === Diabetic foot ulcer is a complication of diabetes. Diabetic foot ulcers are classified as either neuropathic, neuroischaemic or ischaemic. Doctors also use the Wagner Grades to describe the severity of an ulcer. The purpose of the Wagner Grades is to allow specialists to better monitor and treat diabetic foot ulcers. This grading system classifies Diabetic foot ulcers using numbers, from 0 to 5. Wagner Grades 0 through 5 are as follows:
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.